



## Clinical trial results:

### A Phase 2, Randomized, Double-blind, Placebo-controlled, 6-Week, Parallel-design Study of the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy

#### Summary

EudraCT number	2017-001042-10
Trial protocol	DE NL IT
Global end of trial date	08 November 2018

#### Results information

Result version number	v1
This version publication date	27 November 2019
First version publication date	27 November 2019

#### Trial information

##### Trial identification

Sponsor protocol code	VX16-150-102
-----------------------	--------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03304522
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Vertex Pharmaceuticals Incorporated
Sponsor organisation address	50 Northern Avenue, Boston, Massachusetts, United States,
Public contact	Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 617 341 6777, medicalinfo@vrtx.com
Scientific contact	Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 617 341 6777, medicalinfo@vrtx.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	05 December 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	12 October 2018
Global end of trial reached?	Yes
Global end of trial date	08 November 2018
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the efficacy of VX-150 for the treatment of pain caused by small fiber neuropathy.

Protection of trial subjects:

The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the International Council on Harmonization (ICH) Guideline for Good Clinical Practice (GCP).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 September 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Italy: 10
Country: Number of subjects enrolled	Netherlands: 6
Country: Number of subjects enrolled	United States: 71
Country: Number of subjects enrolled	Germany: 2
Worldwide total number of subjects	89
EEA total number of subjects	18

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	66
From 65 to 84 years	23
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 89 subjects were enrolled and randomized in the study.

### Period 1

Period 1 title	Overall Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	VX-150

Arm description:

Subjects received VX-150 once daily for 6 weeks.

Arm type	Experimental
Investigational medicinal product name	VX-150
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects received VX-150 once daily.

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Subjects received placebo matched to VX-150 once daily for 6 weeks.

Arm type	Placebo
Investigational medicinal product name	Placebo (matched to VX-150)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects received placebo matched to VX-150 once daily.

<b>Number of subjects in period 1</b>	VX-150	Placebo
Started	46	43
Completed	45	35
Not completed	1	8
Other	-	1

Withdrawal of consent (for other reason)	-	2
Adverse event	-	4
Withdrawal of consent (due to lack of efficacy)	1	1

## Baseline characteristics

### Reporting groups

Reporting group title	VX-150
-----------------------	--------

Reporting group description:

Subjects received VX-150 once daily for 6 weeks.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects received placebo matched to VX-150 once daily for 6 weeks.

Reporting group values	VX-150	Placebo	Total
Number of subjects	46	43	89
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	55.1 ± 12.34	58.1 ± 11.86	-
Gender categorical Units: Subjects			
Female	22	21	43
Male	24	22	46

## End points

### End points reporting groups

Reporting group title	VX-150
Reporting group description: Subjects received VX-150 once daily for 6 weeks.	
Reporting group title	Placebo
Reporting group description: Subjects received placebo matched to VX-150 once daily for 6 weeks.	

### Primary: Change From Baseline in Weekly Average of Daily Pain Intensity on the 11 Point Numeric Rating Scale (NRS) Score

End point title	Change From Baseline in Weekly Average of Daily Pain Intensity on the 11 Point Numeric Rating Scale (NRS) Score
End point description: Pain intensity was evaluated using the 11-point NRS (where 0 signified no pain and 10 signified worst imaginable pain).	
End point type	Primary
End point timeframe: At Week 6	

End point values	VX-150	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	46	43		
Units: units on a scale				
least squares mean (standard error)	-2.018 ( $\pm$ 0.274)	-0.933 ( $\pm$ 0.287)		

### Statistical analyses

Statistical analysis title	Statistical Analysis
Comparison groups	VX-150 v Placebo
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS Mean Difference
Point estimate	-1.085
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.876
upper limit	-0.293



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug up to safety follow-up (up to 10 weeks)

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.1
--------------------	------

### Reporting groups

Reporting group title	VX-150
-----------------------	--------

Reporting group description:

Subjects received VX-150 once daily for 6 weeks.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects received placebo matched to VX-150 once daily for 6 weeks.

Serious adverse events	VX-150	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 46 (0.00%)	3 / 43 (6.98%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Tendon rupture			
subjects affected / exposed	0 / 46 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 46 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Diverticulitis			
subjects affected / exposed	0 / 46 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	



Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	VX-150	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	16 / 46 (34.78%)	7 / 43 (16.28%)	
Nervous system disorders			
Headache			
subjects affected / exposed	11 / 46 (23.91%)	5 / 43 (11.63%)	
occurrences (all)	14	6	
Gastrointestinal disorders			
Dry mouth			
subjects affected / exposed	3 / 46 (6.52%)	1 / 43 (2.33%)	
occurrences (all)	3	1	
Nausea			
subjects affected / exposed	3 / 46 (6.52%)	1 / 43 (2.33%)	
occurrences (all)	3	1	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	3 / 46 (6.52%)	1 / 43 (2.33%)	
occurrences (all)	3	1	
Muscle spasms			
subjects affected / exposed	3 / 46 (6.52%)	0 / 43 (0.00%)	
occurrences (all)	3	0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
21 April 2017	Amended inclusion criteria to clarify the study population and Body Mass Index (BMI)
19 May 2017	Amended the dose limit of VX-150
11 August 2017	Allowed inclusion of women of childbearing potential; updated the upper limit of BMI and the visit requirements
13 April 2018	Updated inclusion and exclusion criteria to facilitate subject recruitment
25 May 2018	The protocol was amended to enable timely assessment of study data to support continued development

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported